Home » USA Broker Ratings » DexCom, Inc. – Consenus Indicates Potential 5.8% Upside

DexCom, Inc. – Consenus Indicates Potential 5.8% Upside

DexCom, Inc. with ticker code (DXCM) have now 15 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 180 and 125 calculating the mean target price we have 162.73. Given that the stocks previous close was at 153.77 this would imply there is a potential upside of 5.8%. There is a 50 day moving average of 148.86 and the 200 day moving average is 135.8. The company has a market cap of $13,741m. You can visit the company’s website by visiting: http://www.dexcom.com

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.